Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 50.21% from the stock’s current price.

Separately, Stifel Nicolaus began coverage on Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock.

Rapport Therapeutics Stock Performance

Rapport Therapeutics stock opened at $23.30 on Tuesday. Rapport Therapeutics has a 12 month low of $18.00 and a 12 month high of $27.11.

Insider Transactions at Rapport Therapeutics

In other news, Director James Healy purchased 44,032 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were purchased at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the acquisition, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.